Future doc, I do agree that both tests do not do a good job of monitoring CRC. I would give a slight edge to Onko Sure for the very slight early warning but the real problem the company will have to overcome is the lack of a marketing force. If it was an Abbott or Roche, that power might be able to have some success but without the force behind any test, they just will run out of gas, i.e. money, before any significant revenue change.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.